CAMBRIDGE, Mass.--(EON: Enhanced Online News)--RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA, today announced the company’s Chief Scientific Officer, Thomas McCauley, Ph.D., will present at the fifth Cold Spring Harbor conference on RNA & Oligonucleotide Therapeutics taking place March 29 - April 1, in Cold Spring Harbor, N.Y.
“Taking a multidimensional approach to the discovery & development of RNA therapeutics”
Dr. McCauley’s presentation titled, “Taking a multidimensional approach to the discovery & development of RNA therapeutics,” will be presented as part of the mRNA therapeutics session on Saturday, April 1.
Additionally, Balkrishen Bhat, Ph.D., RaNA’s Vice President of Chemistry, will present as chairperson at Cambridge Healthtech Institute’s Second Annual Oligonucleotide and Peptide Therapeutics Conference in Cambridge, Mass., on March 28. Dr. Bhat will present an overview of RaNA’s mRNA protein up-regulation platforms and will moderate a session about delivery challenges and opportunities in the RNA therapeutics space.
About RaNA Therapeutics
RaNA Therapeutics is a leading biotechnology company committed to the development of next generation RNA-targeted medicines. RaNA’s mission is to improve the lives of people suffering from serious life-altering diseases by creating precision medicines that can change the course of their condition. RaNA’s technology has broad therapeutic potential to treat a wide range of diseases, including rare genetic disorders. For more information about the company and its platforms, please visit www.ranarx.com.